Bimekizumab 是一种人源化单克隆抗体，可选择性中和 IL-17A 和 IL-17F ｜ MedChemExpress (MCE)

Bimekizumab

CAS：1418205-77-2

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) 是一种人源化单克隆抗体，可选择性中和 IL-17A 和 IL-17F。这两种细胞因子都能够促进成骨的人骨膜衍生细胞 (hPDC) 分化。因此，Bimekizumab 的应用，可以阻断炎症驱动的成骨分化。

体外：Bimekizumab (10 μg/mL; 1 h) results dual neutralisation of IL-17A and IL-17F, leads to osteocommitment of hPDCs by AS serum is suppressed[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献：

[1]. Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.